Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2024 and Provides Business Update
Galectin Therapeutics (NASDAQ: GALT) reported its Q1 2024 financial results and provided a business update. The NAVIGATE Phase 2b/3 trial of belapectin in liver cirrhosis due to MASH continues as planned, with an interim top-line readout expected late Q4 2024 after a positive fifth DSMB meeting.
Q1 financials show $23.6M in cash with an additional $10M available from a new line of credit. R&D expenses decreased to $8.1M from $8.8M YoY, while G&A expenses increased slightly to $1.6M from $1.5M. The net loss remained constant at $11.5M or ($0.19) per share YoY.
Corporate updates include the appointment of Dr. Khurram Jamil as VP of Clinical Development. The company mourns the loss of Dr. Stephen A. Harrison, a key figure in the belapectin program.
- The NAVIGATE Phase 2b/3 trial of belapectin continues without modifications, indicating a good safety profile.
- The trial is on track for an interim top-line readout in late Q4 2024, suggesting maintained progress.
- Galectin has $23.6M in cash and an additional $20M in available credit, providing financial stability.
- R&D expenses decreased by $0.7M year-over-year, indicating efficient cost management.
- Appointment of Dr. Khurram Jamil as VP of Clinical Development strengthens the leadership team.
- Net loss remained constant at $11.5M or ($0.19) per share YoY, indicating ongoing financial challenges.
- G&A expenses increased slightly to $1.6M from $1.5M, contributing to overall losses.
- Dependence on lines of credit for funding operations could imply financial strain.
- No immediate revenue or profitability milestones mentioned in the update.
- Loss of Dr. Stephen A. Harrison may impact the belapectin program's momentum.
Insights
The financial highlights reveal that Galectin Therapeutics is maintaining a steady course with adequate liquidity to sustain operations until May 2025. This financial stability is important given the ongoing expenditure on research and development (R&D) for the NAVIGATE trial.
Notably, R&D expenses have decreased slightly from
General and Administrative (G&A) expenses have seen a minor increase, which is within reasonable limits for growing organizations. The existing lines of credit amounting to
Investors should monitor the interim top-line data readout expected in late Q4 2024, as this will likely be a important catalyst for stock movement. If the results are positive, it may lead to increased investor confidence and potential stock appreciation. Conversely, any negative outcomes could impact the company's financial health and investor sentiment.
The continuation of the NAVIGATE Phase 2b/3 trial without modifications, as recommended by the Data Safety and Monitoring Board (DSMB), is a critical indicator of belapectin's safety profile. This is particularly significant given the patient population, which includes individuals with liver cirrhosis due to metabolic dysfunction-associated steatohepatitis (MASH).
Belapectin targets galectin-3, a protein involved in fibrosis and MASH pathogenesis. The drug's progress in clinical trials with a fast-track designation from the FDA emphasizes its potential in addressing a significant unmet medical need. Investors should understand that the positive DSMB recommendation aligns with the company's strategic milestones and regulatory pathway.
The shift in clinical outcomes to prevention of esophageal varices as championed by the late Dr. Stephen A. Harrison is noteworthy. This endpoint is less subjective and aligns more closely with real-world clinical practices compared to traditional liver biopsies, potentially accelerating the approval process if results are favorable.
Looking ahead, if the interim analysis readout from the Phase 2b portion confirms efficacy, it would not only validate the therapeutic potential of belapectin but also enhance the company's valuation and market positioning.
- Fifth Data and Safety Monitoring Board (DSMB) meeting recommended the continuation, without modifications, of the Phase 2b/3 NAVIGATE study of belapectin in liver cirrhosis due to metabolic dysfunction-associated steatohepatitis (MASH)
- NAVIGATE trial remains on track for interim top-line readout late in the fourth quarter of 2024
NORCROSS, Ga., May 15, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the quarter ended March 31, 2024.
Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, said “This quarter we remained laser-focused on progressing the NAVIGATE Phase 2b/3 trial of belapectin, which has a Fast Track Designation from the U.S. Food & Drug Administration. As recently reported, we had another positive outcome from the fifth meeting of our independent DSMB, recommending the continuation of the trial without any modifications. This fifth recommendation is another testament to belapectin’s encouraging safety profile, which is key considering the patient population in this trial. We look forward to sharing the top-line interim analysis readout from the Phase 2b portion of the NAVIGATE trial late in the fourth quarter of 2024.”
Pol Boudes, M.D., Chief Medical Officer added, “We are deeply saddened by the recent passing of Dr. Stephen A. Harrison. Stephen was involved in the belapectin clinical program since its inception. As the coordinating investigator of NAVIGATE, he was also a driving force to change the way we are designing clinical research in cirrhotic patients. Most notably, Stephen championed the prevention of esophageal varices as a clinical outcome that is both less subjective and more closely related to real world clinical practice than liver biopsies. We are forever grateful for his contributions to Galectin and will remember his exemplary qualities as we continue his legacy to bring hope to cirrhotic patients.”
Belapectin Program Q1 2024 and Recent Highlights
Belapectin is a complex carbohydrate drug that targets galectin-3, a critical protein in the pathogenesis of MASH and fibrosis.
MASH Cirrhosis
- The NAVIGATE Phase 2b/3 trial (NCT04365868) evaluating the efficacy and safety of belapectin for the prevention of esophageal varices in MASH in 357 patients across 14 countries on five continents is progressing as planned.
- The fifth Data Safety and Monitoring Board (DSMB) meeting authorized the continuation of the trial as designed and without modifications.
- Interim top-line data readout from the Phase 2b portion of the trial is anticipated late in the fourth quarter of 2024.
Corporate Updates
- Appointed Khurram Jamil, M.D. as Vice President of Clinical Development.
Q1 2024 Financial Highlights
- As of March 31, 2024, the Company had
$23.6 million of cash and cash equivalents. Additionally, the Company has$10 million remaining available under a$60 million line of credit provided by its chairman of the board to fund operations and$10 million available from a more recently executed line of credit also provided by our chairman. The Company believes it has sufficient cash to fund currently planned operations and research and development activities through May 15, 2025. - Research and development expenses for the quarter ended March 31, 2024 were
$8.1 million compared with$8.8 million for the same period in 2023. The decrease was primarily due to timing of incurrence of expenditures related to our NAVIGATE clinical trial. - General and administrative expenses for the quarter ended March 31, 2024 were
$1.6 million , compared to$1.5 million for the quarter ended quarter ended March 31, 2023. - For the quarter ended quarter ended March 31, 2024, the Company reported a net loss applicable to common stockholders of
$11.5 million , or ($0.19) per share, compared to a net loss applicable to common stockholders of$11.5 million , or ($0.19) per share for the quarter ended March 31, 2023. - These results are included in the Company's Quarterly Report on Form 10-Q as of and for the period ended March 31, 2024, which has been filed with the U.S. Securities and Exchange Commission and is available at www.sec.gov.
About Galectin Therapeutics
Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Galectin’s lead drug belapectin is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases, for which it has Fast Track designation by the U.S. Food and Drug Administration. The lead development program is in metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis, or NASH) with cirrhosis, the most advanced form of MASH-related fibrosis. Liver cirrhosis is one of the most pressing medical needs and a significant drug development opportunity. Additional development programs are in treatment of combination immunotherapy for advanced head and neck cancers and other malignancies. Advancement of these additional clinical programs is largely dependent on finding a suitable partner. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. Additional information is available at www.galectintherapeutics.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as “may,” “estimate,” “could,” “expect,” “look forward,” “believe,” “hope” and others. They are based on management’s current expectations and are subject to factors and uncertainties that could cause actual results to differ materially from those described in the statements. These statements include those regarding the hope that Galectin’s development program for belapectin will lead to the first therapy for the treatment of MASH, formerly known as NASH, with cirrhosis and those regarding the hope that our lead compounds will be successful in cancer immunotherapy and in other therapeutic indications. Factors that could cause actual performance to differ materially from those discussed in the forward-looking statements include, among others, that trial endpoints required by the FDA may not be achieved; Galectin may not be successful in developing effective treatments and/or obtaining the requisite approvals for the use of belapectin or any of its other drugs in development; the Company may not be successful in scaling up manufacturing and meeting requirements related to chemistry, manufacturing and control matters; the Company’s current clinical trial and any future clinical studies may not produce positive results in a timely fashion, if at all, and could require larger and longer trials, which would be time consuming and costly; plans regarding development, approval and marketing of any of Galectin’s drugs are subject to change at any time based on the changing needs of the Company as determined by management and regulatory agencies; regardless of the results of any of its development programs, Galectin may be unsuccessful in developing partnerships with other companies or raising additional capital that would allow it to further develop and/or fund any studies or trials. Galectin has incurred operating losses since inception, and its ability to successfully develop and market drugs may be impacted by its ability to manage costs and finance continuing operations. For a discussion of additional factors impacting Galectin’s business, see the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, and subsequent filings with the SEC. You should not place undue reliance on forward-looking statements. Although subsequent events may cause its views to change, management disclaims any obligation to update forward-looking statements.
Company Contact:
Jack Callicutt, Chief Financial Officer
(678) 620-3186
ir@galectintherapeutics.com
Investors Relations Contacts:
Kevin Gardner
kgardner@lifesciadvisors.com
Chris Calabrese
ccalabrese@lifesciadvisors.com
Galectin Therapeutics and its associated logo is a registered trademark of Galectin Therapeutics Inc. Belapectin is the USAN assigned name for Galectin Therapeutics’ galectin-3 inhibitor belapectin.
Condensed Consolidated Statements of Operations
| Three Months Ended March 31, | ||||||
| 2024 | 2023 | |||||
| (in thousands) | ||||||
| Operating expenses: | ||||||
| Research and development | $ | 8,054 | $ | 8,799 | ||
| General and administrative | 1,594 | 1,543 | ||||
| Total operating expenses | 9,648 | 10,342 | ||||
| Total operating loss | (9,648 | ) | (10,342 | ) | ||
| Other income (expense): | ||||||
| Interest income | 80 | 44 | ||||
| Interest expense | (1,052 | ) | (460 | ) | ||
| Change in fair value of derivatives | (869 | ) | (769 | ) | ||
| Total other income | (1,841 | ) | (1,185 | ) | ||
| Net loss | $ | (11,489 | ) | $ | (11,527 | ) |
| Preferred stock dividends | (8 | ) | 0 | |||
| Net loss applicable to common stock | $ | (11,497 | ) | $ | (11,527 | ) |
| Basic and diluted net loss per share | $ | (0.19 | ) | $ | (0.19 | ) |
| Shares used in computing basic and diluted net loss per share | 61,976 | 59,480 | ||||
Condensed Consolidated Balance Sheet Data
| March 31, 2024 | December 31, 2023 | |||||
| (in thousands) | ||||||
| Cash and cash equivalents …… | $ | 23,555 | $ | 25,660 | ||
| Total assets……………………...… | 25,890 | 28,200 | ||||
| Total current liabilities…..….. | 12,633 | 15,676 | ||||
| Total liabilities.………………..….. | 96,976 | 88,441 | ||||
| Total redeemable, convertible preferred stock…. | 1,723 | 1,723 | ||||
| Total stockholders’ equity (deficit) ….. | $ | (72,809 | ) | $ | (61,964 | ) |
FAQ
What are the financial results of Galectin Therapeutics for Q1 2024?
What is the status of the NAVIGATE trial for belapectin?
How much did Galectin Therapeutics spend on R&D in Q1 2024?
What is the cash position of Galectin Therapeutics as of Q1 2024?
Who was recently appointed as VP of Clinical Development at Galectin Therapeutics?
